Last updated: 2026-10-12 23:53:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Madrigal Pharmaceuticals, Inc. (MDGL) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $467.22, with a market capitalisation of $10.90B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $393.61 to $615.00. This page covers its latest market performance, valuation, price trends and company information.
$10.90B | |
$471.75 | |
$615.00 | |
$6.60 | |
$471.75 | |
431.21K | |
289.58K | |
-- | |
$615.00 | |
$393.61 | |
-- | |
-- |
Madrigal Pharmaceuticals, Inc. (MDGL) is trading at $467.98 in after-hours trading as of 2026-10-12 23:31:00, down 0.80% ($3.77) from the regular-session close of $471.75.
After-hours trading shows how investors are pricing MDGL after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, Madrigal Pharmaceuticals, Inc. (MDGL) moved from $499.71 to $467.22, representing a decline of 6.50% ($32.50).
The stock traded between $460.79 and $510.00 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 287.74 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 33.2%
MDGL is currently trading at $467.22, placing it 33.2% of the way from its 52-week low of $393.61 to its 52-week high of $615.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 915 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Madrigal Pharmaceuticals, Inc. (MDGL) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.